Effect of age on the efficacy and safety of Panax notoginseng saponins in acute ischemic stroke: a prespecified secondary analysis of the PANDA study

Table 2 Secondary Efficacy Outcomes in Xuesaitong and Placebo Groups by Age Subgroup

Outcomes	Age < 65 years				Age ≥ 65 years
Outcomes	Xuesaitong group	Placebo group	P value*	Interaction effect^a (Time*Group)	Xuesaitong group	Placebo group	P value*	Interaction effect^a (Time*Group)
NIHSS^b score
Score within 3 mo, median (IQR)	1 (0 to 3)	1 (0 to 3)	0.562	NA	1 (0 to 3)	2 (0 to 3)	0.004**	NA
Score change from baseline to 3 mo, median (IQR)	− 4 (− 5 to − 3)	− 4 (− 5 to − 3)	0.130	NA	− 4 (− 5 to − 3)	− 4 (− 5 to − 2)	0.083	NA
EQ- 5D^c score
Score within 3 mo, median (IQR)	90 (80 to 95)	90 (80 to 95)	0.524	0.870	90 (80 to 95)	90 (80 to 95)	0.008**	0.272
Score within 12 mo, median (IQR)	95 (90 to 98)	95 (90 to 96)	0.200	0.870	95 (90 to 98)	90 (90 to 95)	0.010**	0.272
BI^d change
Score change from baseline to 3 mo, median (IQR)	15 (5 to 35)	15 (5 to 30)	0.052	0.553	20 (5 to 35)	15 (5 to 30)	0.045**	0.620
Score change from baseline to 12 mo, median (IQR)	20 (5 to 40)	20 (5 to 40)	0.214	0.553	25 (5 to 40)	20 (5 to 40)	0.527	0.620

BI, Barthel Index; EQ- 5D, EuroQoL Group 5-Dimension; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; Data are presented as median with interquartile ranges (IQR) of patients unless otherwise indicated
*Wilcoxon rank-sum test was applied. The tests were 2-sided. P value of less than 0.05 was considered significant
^aAn interaction P value less than 0.05 indicated that the treatment effect was significantly influenced or modified by time
^bNIHSS score indicated the severity of neurological deficits, ranging from 0 to 42, with higher scores indicating more severe strokes
^cEQ- 5D score referred to 5 dimensions that describe health states, including mobility, usual activities, self-care, feelings of pain or discomfort, feelings of anxiety or depression
^dBI was an ordinal scale which measured a person’s ability to complete activities of daily living (ADL)
**The difference between groups as statistically significant (P value < 0.05)

ISSN: 1749-8546